American Diabetes Association 79th Scientific Sessions

June 7-11, 2019; San Francisco, CA; Category Document – Notable Posters

Executive Highlights

  • This category document features 50 posters (including late-breakers), our top picks for posters at ADA 2019. These abstracts represent the most notable posters on the agenda in our view – 25 in diabetes therapy and 25 in diabetes tech – out of nearly 2,200 total posters and late-breakers being presented at the meeting.

  • In therapy, we’re featuring seven late-breakers, starting with a post-hoc examining open-label SGLT-2 use in the EXSCEL CVOT for GLP-1 Bydureon, with an eye toward renal outcomes (see Dr. John Buse at EASD 2018). Highly-anticipated results from the phase 2 dosing study of Lilly’s GLP-1/GIP dual agonist tirzepatide will be presented on Sunday (993-P), as will data examining hypoglycemia and CV events/mortality in the CARMELINA CVOT for DPP-4 Tradjenta (388-P). ADA 2019 will be a big meeting for novel and next-gen insulins: PRONTO-T1D and PRONTO-T2D data for Lilly’s URLi (1089-P, 1100-P) will be presented in two posters, a late breaker features Gemelli 1 data for Sanofi’s rapid-acting SAR341402 in type 1 (129-LB), and we’ll also see new data on Sanofi’s Toujeo vs. first-gen basals (128-LB). Adjunct therapy for type 1 will also be a focus, with data on the impact of sotagliflozin on renal function, albuminuria, and blood pressure in type 1 adults (1196-P) and pooled analysis of the DEPICT-1 and -2 studies of dapagliflozin in type 1 (1231-P). We’re very much looking forward to posters on patient preferences for adjunct therapy (1199-P) and the M-EASE study further examining low-dose empagliflozin in type 1 (1198-P).

  • In tech, we’re highlighting 10 late-breakers: not to be missed is a poster on the CGM-based clinical target recommendations from the international consensus on time-in-range (2-LB). Other posters focused on outcomes beyond A1c include the impact on quality of life of glucose excursions >140 mg/dl (75-LB); an Onduo poster on the ability for A1c to predict time-in-range (105-LB); real-world hypoglycemia outcomes of Tandem’s Basal-IQ (120-LB); patient experiences with DIY systems (124-LB); and time-in-range data from what could be the Swedish pilot of Novo Nordisk’s connected insulin pen (1076-P). We’re also excited for a late-breaker examining the effects of three-monthly retrospective CGM use in primary care for type 2 (102-LB) and a poster on Beta Bionics’ iLet device in children and adolescents (1063-P). Hospital care is a theme too, with posters on the accuracy of FreeStyle Libre Pro in hospitalized patients (908-P), closed loop in the hospital (1036-P), and reducing hypoglycemia in the noncritical care setting with the Glucose Telemetry System (1246-P). An analysis of two-year Virta data will be shared (759-P) in digital health, as well as real-world Sugar.IQ data (939-P), a sub-analysis of the CONCEPTT trial investigating CGM in pregnancy (1407-P), and multiple posters on extended infusion set wear (127-LB, 1049-P) and DIY Looping experiences (84-LB, 117-LB).

The ADA offers an online itinerary planner and mobile app that you can use to search for sessions and abstracts as well as organize your conference schedule. Each Abstract ID in this document has been hyperlinked to the session’s page on the itinerary planner to help you assemble your personal schedule.

Embargoed abstracts will go live on the ADA itinerary planner at 5:00 PM EDT on Tuesday, June 4, 2019. Please note: while the abstracts are publicly available on the ADA itinerary planner (and linked to in our category documents), they are still under embargo until the ADA meeting. See the ADA embargo policy for specifics on when each individual embargo lifts.

For more recommendations on how to make the best use of our category documents, see our “What is a Category Document” tip sheet.

Diabetes Therapy

Abstract ID

Abstract Title

Authors

Day

Time

Categories

6-LB

Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL

Lindsay E Clegg

Sunday, June 9

12:00 PM - 1:00 PM

GLP-1 Agonists, SGLT Inhibitors

13-LB

Nasal vs. Injected Glucagon: User Experience Results of a Simulated Severe Hypoglycemia Study

Julie Settles

Sunday, June 9

12:00 PM - 1:00 PM

Novel Therapies

56-LB

HCP Information: Drowning in Resources, Lacking Confidence?

James M McDermott

Sunday, June 9

12:00 PM - 1:00 PM

Policy, Reimbursement, and Education

128-LB

Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation Basal Insulins (BI) in Insulin-Naïve Type 2 Diabetes (T2D) Patients (Pts) With and Without Cardiovascular Disease (CVD): Outcomes of the Randomized Pragmatic Real-Life Clinical Trial

Juan P Frias

Sunday, June 9

 

12:00 PM - 1:00 PM

Insulin

129-LB

Similar Efficacy, Safety, and Immunogenicity in People with Diabetes Using SAR341402 or Insulin Aspart: Gemelli 1 Study

Satish K Garg

Sunday, June 9

 

12:00 PM - 1:00 PM

Insulin

140-LB

NGM313, a Novel Activator of b-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects

Alex DePaoli

Sunday, June 9

12:00 PM - 1:00 PM

NAFLD/NASH

164-LB

A Randomized Controlled Trial to Compare the Glycemic Effects of Dapagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Gliclazide Modified Release, a Sulfonylurea, Assessed by Continuous Glucose Monitoring among People with Type 2

Andre GD Vianna

Sunday, June 9

12:00 PM - 1:00 PM

SGLT Inhibitors

388-P

Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial

Julio Rosenstock

Sunday, June 9

12:00 PM - 1:00 PM

Diabetes Complications

895-P

Effects of Dapagliflozin, Metformin, or Exercise on Markers of Cardiometabolic Risk: The PRE-D Trial

Marit E Jørgensen

Saturday, June 8

11:30 AM - 12:30 PM

Obesity, prediabetes, & remission

901-P

Effects of Dapagliflozin, Metformin, or Exercise on Glycaemic Variability and Mean Glucose Levels in Prediabetes: The PRE-D Trial

Kristine Færch

Saturday, June 8

11:30 AM - 12:30 PM

Obesity, prediabetes, & remission

986-P

Efficacy of Semaglutide by Background Sodium-Glucose Cotransporter 2 Inhibitor: A Post Hoc Analysis of SUSTAIN 9

Bernard Zinman

Sunday, June 9

12:00 PM - 1:00 PM

GLP-1 Agonists, SGLT Inhibitors

993-P

A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes

Juan P Frias

Sunday, June 9

12:00 PM - 1:00 PM

Novel Therapies, GLP-1 Agonists

1011-P

Therapeutic Potential of Novel Combination of a Long-Acting Glucagon Analog (HM15136) and Antidiabetic Drugs for the Treatment of Obesity

Jong Suk Lee

Sunday, June 9

12:00 PM - 1:00 PM

Obesity, prediabetes, & remission

1017-P

Continuous Glucose Monitoring Reveals Comprehensive Glucose Control with MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity

Victoria E Parker

Sunday, June 9

12:00 PM - 1:00 PM

GLP-1 Agonists

1089-P

Ultra Rapid Lispro (URLi) Improves Postprandial Glucose (PPG) Control and Time in Range (TIR) in T1D Compared with Humalog (Lispro): PRONTO-T1D Continuous Glucose Monitoring (CGM) Substudy

Bruce W Bode

Saturday, June 8

11:30 AM - 12:30 PM

Insulin

1100-P

Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) in Patients with TYPE 2 DIABETES

Jennifer Leohr

Saturday, June 8

11:30 AM - 12:30 PM

Insulin

1132-P

Real-World Clinical Use of iGlarLixi in a Large U.S. Electronic Medical Records Database

Juan P Frias

Sunday, June 9

12:00 PM - 1:00 PM

GLP-1 Agonists

1191-P

Sotagliflozin Reduces Glucose Variability and Risk for Hyperglycemia in Adults with Type 1 Diabetes

Boris Kovatchev

Sunday, June 9

12:00 PM - 1:00 PM

Type 1 “Cure” Therapies, Adjuncts, and Pathophysiology, SGLT Inhibitors

1193-P

Health-Care Costs and Medication Burden in Routine Care Initiators of Empagliflozin: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

Ajinkya Pawar

Sunday, June 9

12:00 PM - 1:00 PM

SGLT Inhibitors

1196-P

The Impact of Sotagliflozin on Renal Function, Albuminuria, and Blood Pressure in Adults with Type 1 Diabetes (T1D)

David Cherney

Sunday, June 9

12:00 PM - 1:00 PM

Type 1 “Cure” Therapies, Adjuncts, and Pathophysiology, SGLT Inhibitors

1198-P

The M-EASE Studies: A Modeling and Simulation Approach to Further Characterize the Efficacy of Low-Dose Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes (T1DM)

Bruce A Perkins

Poster Hall (Hall F, North, Exhibition Level)

12:00 PM - 1:00 PM

Type 1 “Cure” Therapies, Adjuncts, and Pathophysiology, SGLT Inhibitors

1199-P

Analysis of Patient Preferences for Adjunct Therapy to Insulin in T1D

Bruce A Perkins

Poster Hall (Hall F, North, Exhibition Level)

12:00 PM - 1:00 PM

Type 1 “Cure” Therapies, Adjuncts, and Pathophysiology, SGLT Inhibitors

1225-P

The Association between Long-Term Glucose Variability (GV), Cardiovascular (CV) Death, and Heart Failure (HF) Outcomes in the EMPA-REG OUTCOME Trial

Anne Pernille Ofstad

Sunday, June 9

12:00 PM - 1:00 PM

SGLT Inhibitors

1231-P

Dapagliflozin (DAPA) in Type 1 Diabetes (T1D): Pooled Outcomes from DEPICT-1 and -2

Paresh Dandona

Poster Hall (Hall F, North, Exhibition Level)

12:00 PM - 1:00 PM

Type 1 “Cure” Therapies, Adjuncts, and Pathophysiology, SGLT Inhibitors

1247-P

Anticipating the Impact of 2019 Guidelines: Use of SGLT2i and GLP-1RA in Patients with Diabetes and Cardiovascular Disease

Elizabeth L Ciemins

Sunday, June 9

12:00 PM - 1:00 PM

Policy, Reimbursement, and Education

 

 

Diabetes Technology

Abstract ID

Abstract Title

Authors

Day

Time

Categories

2-LB

CGM-Based Clinical Targets: Recommendations from the International Consensus on Time-in-Range (TIR)

Tadej Battelino MD, PhD

Sunday, June 9

12:00 PM - 1:00 PM

Glucose Monitoring, Beyond A1c and Hypoglycemia

37-LB

Diabetic Retinopathy (DR) Screening Performance of an Artificial Intelligence (AI) System: Analysis from a Pivotal Multicenter Prospective Clinical Trial

Bruce W Bode MD

Sunday, June 9

12:00 PM - 1:00 PM

Digital Health

75-LB

Glucose Excursions over 140 mg/dL May Impact Quality of Life in Patients with Well-Managed Type 1 Diabetes

Allyson Hughes PhD

Sunday, June 9

12:00 PM - 1:00 PM

Glucose Monitoring, Beyond A1c and Hypoglycemia

84-LB

Real-World Psychosocial Outcomes and Ease of Use Predict Trust in Automated Insulin Delivery (AID) Systems

Michelle L Manning MA

Sunday, June 9

12:00 PM - 1:00 PM

Closing the Loop, Pumps, and Insulin Delivery,

102-LB

GP-OSMOTIC: An RCT to Determine the Effect of 3-Monthly Retrospective Continuous Glucose Monitoring (rCGM) on 12-Month HbA1c in Adults with Type 2 Diabetes (T2D) in Primary Care

John Furler MBBS, PhD

Sunday, June 9

12:00 PM - 1:00 PM

Glucose Monitoring

105-LB

Does HbA1c Accurately Predict Time-in-Range?

Ronald F Dixon MD

Sunday, June 9

12:00 PM - 1:00 PM

Glucose Monitoring, Beyond A1c and Hypoglycemia

117-LB

DIWHY: Factors Influencing Motivation, Barriers, and Duration of DIY Artificial Pancreas System Use among Real-World Users

Dana M Lewis BA

Sunday, June 9

12:00 PM - 1:00 PM

Closing the Loop, Pumps, and Insulin Delivery,

120-LB

Early Real-World Hypoglycemia Outcomes with Use of the Tandem Basal-IQ Technology System

Jordan E Pinsker MD

Sunday, June 9

12:00 PM - 1:00 PM

Closing the Loop, Pumps, and Insulin Delivery, Beyond A1c and Hypoglycemia

122-LB

iSage: Successful Basal Insulin Titration Managed by a Prescription-Only Digital Therapy for T2DM

Kristine Grdinovac MD

Sunday, June 9

12:00 PM - 1:00 PM

Digital Health, Closing the Loop, Pumps, and Insulin Delivery

126-LB

Improved Insulin Adherence after Introduction of a Smart Connected Insulin Pen

Peter Adolfsson MD, PhD

Sunday, June 9

12:00 PM - 1:00 PM

Closing the Loop, Pumps, and Insulin Delivery

127-LB

Longevity of the Coated ConvaTec Infusion Set with Lantern Technology

Rayhan Lal MD

Sunday, June 9

12:00 PM - 1:00 PM

Closing the Loop, Pumps, and Insulin Delivery

759-P

Analysis of a Two-Year Continuous Care Intervention Including Nutritional Ketosis—Exploring Baseline Predictors of Diabetes Reversal and Remission

Shaminie J Athinarayanan PhD

Monday, June 10

12:00 PM - 1:00 PM

Digital Health

908-P

Accuracy Comparison of the Freestyle Libre Pro Continuous Glucose Monitoring (CGM) and Point-of-Care (POC) Testing in Noncritically Ill Hospitalized Patients with Type 2 Diabetes Treated with Basal-Bolus Insulin Regimen

Rodolfo J Galindo MD

Saturday, June 8

11:30 AM - 12:30 PM

Glucose Monitoring

936-P

Annual Cost to Achieve Cost Effectiveness of Continuous Glucose Monitoring in Hypoglycemia-Unaware Type 1 Diabetes Patients Using Intensive Insulin in the United Kingdom

S. Pinar Bilir MS

Saturday, June 8

11:30 AM - 12:30 PM

Glucose Monitoring, Beyond A1c and Hypoglycemia

939-P

Real-World Performance of the Guardian Connect System with Sugar.IQ

Siddharth Arunachalam MS

Saturday, June 8

11:30 AM - 12:30 PM

Glucose Monitoring, Digital Health

976-P

Post Market Clinical Follow-Up (PMCF) Registry to Demonstrate the Long Term Safety of the Eversense CGM System

Grace Carlson MD, MBA

Saturday, June 8

11:30 AM - 12:30 PM

Glucose Monitoring

1036-P

Closed-Loop Glucose Control System for In-Hospital Use: Extended Control Trials

Niels Ejskjaer MD, PhD

Saturday, June 8

11:30 AM - 12:30 PM

Closing the Loop, Pumps, and Insulin Delivery

1037-P

Glucose Control following Missed and Late Meal Boluses with a Medtronic Enhanced-Hybrid Closed-Loop (E-HCL) System

David N O'Neal MD

Saturday, June 8

11:30 AM - 12:30 PM

Closing the Loop, Pumps, and Insulin Delivery

1038-P

Results of Interim Analysis of a Randomized Crossover Study in Type 1 Diabetes (T1D) of a Dual-Hormone Closed-Loop System with Xerisol Glucagon vs. Insulin-Only Closed-Loop System vs. a Predictive Low Glucose Suspend System

Leah M Wilson MD

Saturday, June 8

11:30 AM - 12:30 PM

Closing the Loop, Pumps, and Insulin Delivery

1041-P

Feasibility Study of a Hybrid Closed-Loop System with Automated Correction Boluses

Revital Nimri MD

Saturday, June 8

11:30 AM - 12:30 PM

Closing the Loop, Pumps, and Insulin Delivery

1049-P

Towards Prolongation of Insulin Pump Catheters Wearing Time Using a Mixture of Insulin and a Nonsteroidal Anti-inflammatory Drug

Rémi Rabasa-Lhoret MD, PhD

Sunday, June 9

12:00 PM - 1:00 PM

Closing the Loop, Pumps, and Insulin Delivery

1063-P

First Test of the iLet, a Purpose-Built Bionic Pancreas Platform, in Children and Adolescents with Type 1 Diabetes

Laya Ekhlaspour MD

Sunday, June 9

12:00 PM - 1:00 PM

Closing the Loop, Pumps, and Insulin Delivery

1076-P

Increased Time-in-Range (TIR) Observed after Introduction of a Connected Insulin Pen

Peter Adolfsson MD, PhD

Sunday, June 9

12:00 PM - 1:00 PM

Closing the Loop, Pumps, and Insulin Delivery, Beyond A1c and Hypoglycemia

1246-P

Reducing Hypoglycemia in the Noncritical Care Setting Using CGM Devices: The Glucose Telemetry System

Elias Spanakis MD

Sunday, June 9

12:00 PM - 1:00 PM

Glucose Monitoring, Beyond A1c and Hypoglycemia

1407-P

Laboratory Glycemic Markers vs. Continuous Glucose Monitoring (CGM) for Prediction of Neonatal Outcomes in Type 1 Diabetes Pregnancy—An Ancillary Study of the CONCEPTT Trial

Claire L Meek MBChB, PhD

Poster Hall (Hall F, North, Exhibition Level)

12:00 PM - 1:00 PM

Glucose Monitoring

 

-- by Peter Rentzepis, Ann Carracher, Maeve Serino, Adam Brown, and Kelly Close